PDF) Statins, Fibrates and Myopathy: Pathophysiological Mechanism, Risk Factors and Laboratory Markers

Statins, Fibrates and Myopathy: Pathophysiological Mechanism, Risk Factors and Laboratory Markers

Novel potassium binders: a clinical update

Design and rationale of a randomized control trial testing the effectiveness of combined therapy with STAtin plus FENOfibrate and statin alone in non-diabetic, combined dyslipidemia patients with non-intervened intermediate coronary artery disease

Muscle- and skeletal-related side-effects of statins: tip of the iceberg? - Johann Auer, Helmut Sinzinger, Barry Franklin, Robert Berent, 2016

IJMS, Free Full-Text

Efficacy and Safety of Pitavastatin in a Real-World Setting: Observational Study Evaluating SaFety in Patient Treated with Pitavastatin in Korea (PROOF Study)

Anti-atherosclerotic therapies: Milestones, challenges, and emerging innovations: Molecular Therapy

Effects of statins on myocarditis: A review of underlying molecular mechanisms - ScienceDirect

triglyc-drugs-Image001.jpg

Risk Factors and Drug Interactions Predisposing to Statin-Induced Myopathy

Statins, fibrates, thiazolidinediones and resveratrol as adjunctive therapies in sepsis: could mitochondria be a common target?, Intensive Care Medicine Experimental

Drug-drug-gene interactions as mediators of adverse drug reactions to diclofenac and statins: a case report and literature review

Atherogenic dyslipidemia in Latin America: prevalence, causes and treatment. Consensus

Statin-Related Myotoxicity: A Comprehensive Review of Pharmacokinetic, Pharmacogenomic and Muscle Components. - Abstract - Europe PMC

Mechanisms of Statin-Induced Myopathy Arteriosclerosis, Thrombosis, and Vascular Biology

The Role of Coenzyme Q10 in Statin-Associated Myopathy: A Systematic Review